Home » Stocks » SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. (SLS)

Stock Price: $3.49 USD -0.07 (-1.97%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $3.54 +0.05 (1.43%) Aug 3, 7:59 PM

Stock Price Chart

Key Info

Market Cap 23.45M
Revenue (ttm) n/a
Net Income (ttm) -18.90M
Shares Out 6.72M
EPS (ttm) -6.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $3.49
Previous Close $3.56
Change ($) -0.07
Change (%) -1.97%
Day's Open 3.55
Day's Range 3.40 - 3.68
Day's Volume 2,994,655
52-Week Range 1.46 - 10.89

More Stats

Market Cap 23.45M
Enterprise Value 16.72M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 6.72M
Float 6.29M
EPS (basic) -9.39
EPS (diluted) -6.73
FCF / Share -3.06
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 166,460
Short Ratio 1.36
Short % of Float 3.09%
Beta 1.72
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.67
Revenue n/a
Operating Income -19.75M
Net Income -18.90M
Free Cash Flow -19.48M
Net Cash 6.72M
Net Cash / Share 1.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -66.16%
ROE -343.23%
ROIC -441.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.00*
Low
9.00
Current: $3.49
High
9.00
Target: 9.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-20.04-31.09-23.04-16.51-34.22-43.90-28.49-21.20-12.49-16.63
Net Income-19.29-27.67-23.75-17.68-63.90-36.61-76.68-34.97-11.49-11.99
Shares Outstanding2.560.260.050.020.01-----
Earnings Per Share-10.92-157.72-522.00-933.00-12,346.24-9,195.92-25,502.55-16,801.68-9,600.96-20,102.01
Operating Cash Flow-17.64-30.42-10.99-11.85-48.16-42.87-28.93-20.97-14.67-10.26
Capital Expenditures-----0.15-0.06-0.32--0.05-0.11
Free Cash Flow-17.64-30.42-10.99-11.85-48.31-42.93-29.25-20.97-14.72-10.36
Cash & Equivalents7.385.4512.756.0530.1323.8547.9935.5911.546.91
Total Debt0.22-10.997.374.748.409.890.060.570.07
Net Cash / Debt7.165.451.76-1.3225.3915.4538.1035.5310.976.84
Assets16.6116.9233.536.4282.1480.4987.9854.9930.977.48
Liabilities10.5211.6731.4611.4268.6343.4382.0927.2320.865.05
Book Value6.095.252.07-5.0013.5137.065.8927.7610.112.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name SELLAS Life Sciences Group, Inc.
Country United States
Employees 5
CEO Angelos M. Stergiou

Stock Information

Ticker Symbol SLS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SLS

Description

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.